Vol.67 No.6 November 2019
In vitro susceptibility study of clinical isolates of Candida and Aspergillus species to caspofungin (Additional Report): a post-marketing surveillance report
1)Medical Affairs, MSD K.K., KITANOMARU SQUARE, 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, Japan
2)Pharmacovigilance, MSD K.K.
3)Non-clinical Development Department, MSD K.K.
4)Clinical Development Department, MSD K.K.
Abstract
As part of a post-marketing survey of caspofungin (CPFG), we previously reported the results of the susceptibility to CPFG of clinical isolates obtained between 2012 and 2014. In the present study, we report the results of evaluation of the in vitro susceptibility to CPFG of 6 Candida species (C. albicans, C. parapsilosis, C. glabrata, C. tropicalis, C. krusei, and C. guilliermondii) and 4 Aspergillus species (A. fumigatus, A. flavus, A. niger, and A. terreus) isolated from patients with suspected fungal infections in Japan between 2015 and 2016 by the broth microdilution methods, M27-A3 and M38-A2, and in accordance with the susceptibility criteria of M27-S3 recommended by the Clinical and Laboratory Standards Institute. The results of both studies were combined to analyze the 5-year trend from 2012 to 2016.
The MIC90 and MEC90 of CPFG for C. albicans (50 isolates/year), C. parapsilosis (30 isolates/year), C. glabrata (30 isolates/year), and A. fumigatus (50 isolates/year) were 0.25, 2, 0.5 and 0.25 μg/mL, respectively, in both 2015 and 2016. The changes in the MIC50/MEC50 and MIC90/MEC90 values of CPFG for all the species tested were within the range of a 2-fold difference during the 5-year period. Furthermore, all the isolates obtained during the same-period were observed to be susceptible to CPFG at MICs and MECs of <2 μg/mL. The results in of our survey revealed no tendency towards reduction in the susceptibility to CPFG of clinical isolates in Japan.
Key word
caspofungin, Candida, Aspergillus, drug susceptibility
Received
December 25, 2018
Accepted
May 21, 2019
Jpn. J. Chemother. 67 (6): 651-659, 2019
